Zhou Ran, Zeng Qiuming, Yang Huan, Xu Yan, Tan Guojun, Liu Hongbo, Wang Lihua, Zhou Hongyu, Zhang Meini, Feng Jinzhou, Jin Tao, Zhang Xinghu, Wang Jiawei, Zhang Xu, Gao Feng, Yang Chunsheng, Bu Bitao, Li Chunyang, Zhang Min, Dong Huiqing, Lin Aiyu, Liu Weibin, Wu Lei, Wang Manxia, Tang Yulan, Wang Honghao, Long Youming, Wang Zhe, Zheng Weihong
Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Neurol. 2021 Apr 8;12:651511. doi: 10.3389/fneur.2021.651511. eCollection 2021.
The prevalence of multiple sclerosis (MS) in China is low, although it has been increasing recently. Owing to the paucity of data on immunotherapy acceptance in the Chinese population, we conducted this study to analyze factors affecting the acceptance of immunotherapy and selection of disease-modifying therapies (DMTs) based on personal and clinical data of patients with MS. In this study, data were obtained from the , which was the first national survey of patients with MS in China. There were 1,212 patients with MS from 31 provinces who were treated at 49 Chinese hospitals over a 4-month period from May 2018 to August 2018, and the patients were asked to complete online questionnaires to assess their understanding of the disease. In general, highly educated patients with frequent relapses were more willing to receive treatment regardless of DMTs or other immunotherapy, and patients with more understanding of the disease opted to be treated. Younger patient population, patients with severe disease course, and those with more symptoms were likely to choose the treatment. Moreover, a higher proportion of women chose to be treated with DMTs than with other immunotherapies. Education status and patient awareness of the disease impact the treatment acceptance in Chinese patients with MS. Therefore, we call for improving the awareness of MS disease and social security to help patients to improve their quality of life.
中国多发性硬化症（MS）的患病率较低，尽管近年来呈上升趋势。由于中国人群中关于免疫疗法接受情况的数据匮乏，我们开展了这项研究，以根据MS患者的个人和临床数据分析影响免疫疗法接受度及疾病修饰疗法（DMT）选择的因素。在本研究中，数据来自于中国首次针对MS患者的全国性调查。2018年5月至2018年8月的4个月期间，来自31个省份的1212例MS患者在中国49家医院接受治疗，这些患者被要求完成在线问卷以评估他们对该疾病的了解程度。总体而言，受过高等教育且频繁复发的患者更愿意接受治疗，无论采用DMT还是其他免疫疗法，对疾病了解更多的患者更倾向于接受治疗。年轻患者群体、病程严重的患者以及症状较多的患者更有可能选择治疗。此外，选择接受DMT治疗的女性比例高于选择其他免疫疗法的女性。教育程度和患者对疾病的认知影响中国MS患者对治疗的接受度。因此，我们呼吁提高对MS疾病的认知和社会保障，以帮助患者提高生活质量。
